GLP-1 agonists: a game changer in pain treatment and addiction.

IF 1.5 Q4 CLINICAL NEUROLOGY
Pain management Pub Date : 2025-10-01 Epub Date: 2025-07-28 DOI:10.1080/17581869.2025.2536998
Sahil Bade, Mark Friedrich B Hurdle, Sohail Bade, Sebastian Encalada, Sharima Kanahan-Osman, Sahil Gupta
{"title":"GLP-1 agonists: a game changer in pain treatment and addiction.","authors":"Sahil Bade, Mark Friedrich B Hurdle, Sohail Bade, Sebastian Encalada, Sharima Kanahan-Osman, Sahil Gupta","doi":"10.1080/17581869.2025.2536998","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic pain imposes a significant healthcare burden, with treatments often limited by side effects, opioid dependency, and preventable surgeries. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), developed for diabetes and obesity, may offer novel analgesia and treat drug-seeking behavior. This review examines the role of GLP-1RAs in pain management, focusing on inflammation, macrophage repolarization, oxidative stress, and dopaminergic pathways in substance use disorders. We conducted a literature search in PubMed and Embase (Ovid) from January 2000 to February 2025, identifying studies on GLP-1RA and pain in headaches, osteoarthritis, diabetic neuropathy, and substance use disorders. GLP-1RAs offer a promising shift in pain management, potentially reducing opioid dependence, preventing surgical interventions, and lowering healthcare costs. While early evidence suggests analgesic and disease-modifying effects beyond weight loss, significant knowledge gaps remain. In osteoarthritis, they appear to reduce inflammation and cartilage degradation, but trials in non-obese, non-comorbid patients are needed. In diabetic neuropathy, GLP-1RAs show potential for nerve repair, but optimal dosing and long-term efficacy need clarification. Preclinical data support GLP-1RAs signaling in migraines, but human studies are lacking. Trials in alcohol addiction show promise, though evidence for other substances remains inconclusive. Larger-scale trials are needed to confirm these findings.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"753-765"},"PeriodicalIF":1.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17581869.2025.2536998","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic pain imposes a significant healthcare burden, with treatments often limited by side effects, opioid dependency, and preventable surgeries. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), developed for diabetes and obesity, may offer novel analgesia and treat drug-seeking behavior. This review examines the role of GLP-1RAs in pain management, focusing on inflammation, macrophage repolarization, oxidative stress, and dopaminergic pathways in substance use disorders. We conducted a literature search in PubMed and Embase (Ovid) from January 2000 to February 2025, identifying studies on GLP-1RA and pain in headaches, osteoarthritis, diabetic neuropathy, and substance use disorders. GLP-1RAs offer a promising shift in pain management, potentially reducing opioid dependence, preventing surgical interventions, and lowering healthcare costs. While early evidence suggests analgesic and disease-modifying effects beyond weight loss, significant knowledge gaps remain. In osteoarthritis, they appear to reduce inflammation and cartilage degradation, but trials in non-obese, non-comorbid patients are needed. In diabetic neuropathy, GLP-1RAs show potential for nerve repair, but optimal dosing and long-term efficacy need clarification. Preclinical data support GLP-1RAs signaling in migraines, but human studies are lacking. Trials in alcohol addiction show promise, though evidence for other substances remains inconclusive. Larger-scale trials are needed to confirm these findings.

GLP-1激动剂:疼痛治疗和成瘾的游戏规则改变者。
慢性疼痛带来了巨大的医疗负担,治疗往往受到副作用、阿片类药物依赖和可预防手术的限制。新的证据表明,胰高血糖素样肽-1受体激动剂(GLP-1RAs),开发用于糖尿病和肥胖,可能提供新的镇痛和治疗药物寻求行为。这篇综述探讨了GLP-1RAs在疼痛管理中的作用,重点关注炎症、巨噬细胞复极化、氧化应激和物质使用障碍中的多巴胺能通路。从2000年1月到2025年2月,我们在PubMed和Embase (Ovid)上进行了文献检索,确定了GLP-1RA和头痛、骨关节炎、糖尿病神经病变和物质使用障碍疼痛的研究。GLP-1RAs为疼痛管理提供了有希望的转变,可能减少阿片类药物依赖,防止手术干预,降低医疗成本。虽然早期的证据表明止痛和改善疾病的作用超出了减肥,但重大的知识差距仍然存在。在骨关节炎中,它们似乎可以减少炎症和软骨退化,但需要在非肥胖、无合并症的患者中进行试验。在糖尿病神经病变中,GLP-1RAs显示出神经修复的潜力,但最佳剂量和长期疗效需要澄清。临床前数据支持GLP-1RAs信号在偏头痛中的作用,但缺乏人体研究。酒精成瘾的试验显示出了希望,尽管其他物质的证据仍不确定。需要更大规模的试验来证实这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pain management
Pain management CLINICAL NEUROLOGY-
CiteScore
2.90
自引率
5.90%
发文量
62
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信